ArticleDiabetes spectrum : a publication of the American Diabetes Association2024
Understanding the Burden of Nonalcoholic Fatty Liver Disease: Time for Action.
Article in Diabetes spectrum : a publication of the American Diabetes Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed.
- Subtyping metabolic dysfunction-associated steatotic liver disease using electronic health record-linked genomic cohorts reveals diverse etiologies and progression.Nature communications · 2026Article
- Epidemiology of Patients With Chronic Liver Disease Presenting to Emergency Departments in Australia.Emergency medicine Australasia : EMA · 2026Article
- Understanding the economic and healthcare burden of metabolic dysfunction-associated steatohepatitis: a real-world claims data analysis from Germany.Journal of comparative effectiveness research · 2026Article
- Awareness of Non-alcoholic Fatty Liver Disease in Makkah, Saudi Arabia: A Cross-Sectional Study.Cureus · 2026Article
- Prediabetic cardiomyopathy is attenuated by hypothalamic PVN oxytocin neuron activation.The Journal of physiology · 2026Article
- Identification of circadian rhythm-associated key genes in metabolic dysfunction-associated fatty liver disease.Clinical and experimental medicine · 2026Article
- Metabolic dysfunction-associated steatotic liver disease and obstructive sleep apnea: A cohort analysis of prevalence and hepatic outcomes.World journal of gastrointestinal pharmacology and therapeutics · 2026Article
- PNPLA3-I148M reduces hepatic triacylglycerol secretion and mitigates diet induced left ventricular diastolic dysfunction.Scientific reports · 2026Article
- Effect of nurse-led phlebotomy on iron stores, insulin resistance, and blood lipids: a systematic review and meta-analysis.BMC nursing · 2026Article
- The global cardiovascular-liver-metabolic syndemic: epidemiology, trends and challenges.Nature reviews. Cardiology · 2026Review
- A Supervised, Online, Home-Based Eccentric Resistance Exercise Program for Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.Gastroenterology research · 2026Article
- Article
- Artificial intelligence‑based quantitative analysis of hepatic fibrosis in carbon tetrachloride-induced mouse model of metabolic dysfunction-associated steatohepatitis.Toxicological research · 2026Article
- One-carbon Metabolism and Epigenetic Elements are Modulated by miR-1914-5p in an in Vitro Model of Steatosis.Cell biochemistry and biophysics · 2026Article
- From Adipose Dysfunction to Multi-Organ Steatosis: Defining the Metabolic Steatotic Axis.Current issues in molecular biology · 2026Review
- Targeting metabolic dysfunction-associated steatotic liver disease with phytosomal silymarin and piperine: A natural alternative to fenofibrate in a rat model.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Liver Biopsy in Metabolic-Associated Steatotic Liver Disease: Accuracy, Challenges, and Alternatives.Cureus · 2026Review
- Virtual Twin-PBPK Modelling: A Step Toward Precision Dosing in Patients with Obesity.The AAPS journal · 2026Article
- Protective role of aqueousFrontiers in endocrinology · 2026Article
- Flaxseed oil and probiotics protect against induced nonalcoholic fatty liver disease (NAFLD) in male rats.Open life sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prevalence of nonalcoholic fatty liver disease (NAFLD) in the United States is 38%, having increased by 50% within the past 3 decades. The estimated NAFLD prevalence among people with type 2 diabetes is 55-70%. The presence of type 2 diabetes is associated with a higher likelihood of progression of NAFLD to fibrosis development, liver transplant, and death. Cardiovascular disease is the main cause of mortality among people with NAFLD, and the risk of death is significantly higher in people with both NAFLD and type 2 diabetes. NAFLD carries high patient and economic burdens but low awareness among both the general public and health care providers. This article reviews the epidemiology of NAFLD and discusses the need for appropriate risk stratification, referral for specialty care, management of cardiometabolic risk factors, and treatment of the disease. The authors present a call to action to raise awareness of NAFLD and address its increasing burden in a systematic and efficient manner.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.